Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on hexarelin. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Hexarelin is not approved by the FDA for any indication and is prohibited in competitive sport under WADA regulations. Consult a qualified healthcare professional before making any health or treatment decisions.
Hexarelin is a synthetic hexapeptide growth hormone secretagogue and the most potent GH-releasing peptide (GHRP) characterized to date. Developed by Mediolanum Farmaceutici in Italy, hexarelin shares the GHS-R1a receptor target of ipamorelin, GHRP-2, and GHRP-6, but distinguishes itself on two pharmacological dimensions: it produces larger GH responses than any other GHRP at equivalent doses, and it binds a second receptor—CD36—that mediates cardioprotective effects entirely independent of the GH axis. This second mechanism makes hexarelin pharmacologically unique in the GH Secretagogues cluster and scientifically interesting beyond its GH-stimulating properties.
The potency advantage comes with tradeoffs. Hexarelin produces the most pronounced cortisol and ACTH stimulation of any GHRP, undermining the clean endocrine profile that makes ipamorelin the preferred GHS-R1a agonist in community protocols. More significantly, hexarelin undergoes the fastest receptor desensitization of all GHRPs—repeated dosing attenuates the GH response within weeks, limiting sustained utility for protocols that depend on maintained GH elevation. These characteristics have pushed hexarelin toward niche applications in community use, while the cardioprotective CD36 research has attracted genuine scientific interest from cardiac researchers studying ischemia and heart failure.
Table of Contents
- What Is Hexarelin?
- Origins and Development
- Mechanism of Action
- The CD36 Receptor: Hexarelin’s Unique Cardioprotective Pathway
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- The Human Studies Landscape
- Safety, Risks, and Limitations
- Legal and Regulatory Status
- Research Protocols and Laboratory Practices
- Dosing in Published Research
- Dosing in Independent Self-Experimentation Communities
- Frequently Asked Questions
- Related Peptides: How Hexarelin Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Quick Facts
| Type | Synthetic hexapeptide GHS-R1a agonist and CD36 ligand |
| Also known as | Examorelin; EP-23905; MF-6003 |
| Sequence | His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular weight | 887.1 Da |
| Target receptors | GHS-R1a (pituitary/hypothalamus) and CD36 (cardiac tissue, macrophages) |
| Mechanism | GHS-R1a agonist → pituitary GH release; CD36 ligand → cardioprotective signaling independent of GH axis |
| Plasma half-life | ~70 minutes (SC administration) |
| Route of administration | Subcutaneous or intravenous injection (research use) |
| Developer | Mediolanum Farmaceutici (Italy) |
| FDA status | Category 3 — not approved for any indication |
| WADA status | Prohibited — S2 (Peptide Hormones, Growth Factors, and Related Substances) |
| Evidence tier | Phase I/II — human GH stimulation and cardiac data exist; no Phase III |
| Key distinction | Most potent GH-releasing hexapeptide; unique CD36-mediated cardioprotective mechanism; fastest desensitization of all GHRPs |
What Is Hexarelin?
Hexarelin (examorelin) is a hexapeptide—six amino acids—with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂. The D-2-MeTrp (D-2-methyltryptophan) at position 2 is the modification that most distinguishes hexarelin from GHRP-6 (which uses D-Trp at position 2) and contributes to both hexarelin’s higher receptor affinity at GHS-R1a and its longer half-life of approximately 70 minutes—substantially longer than GHRP-6’s 15–20 minutes.
The compound acts as a full agonist at GHS-R1a, producing GH release through the IP3/calcium intracellular pathway. It additionally binds CD36, a scavenger receptor expressed in cardiac tissue, macrophages, and vascular endothelium. The CD36-mediated effects include activation of anti-apoptotic signaling pathways in cardiomyocytes, reduction of oxidative stress during ischemia-reperfusion injury, and modulation of macrophage inflammatory responses. These effects are preserved in GH-deficient and hypophysectomized animals, confirming they are GH-axis independent.
Plain English
Hexarelin is the only GHRP that talks to two different receptors: one on the pituitary (releasing GH) and one on heart cells (protecting them during oxygen deprivation). The heart-protective effect works even without any growth hormone involved—a completely separate mechanism.
Origins and Development
Hexarelin was developed by Mediolanum Farmaceutici as part of Italy’s substantial contribution to GHRP pharmacology research in the 1990s. The compound was studied in multiple academic centers—particularly in Turin under Ezio Ghigo and colleagues—and generated a body of Phase I/II clinical research covering GH stimulation, desensitization kinetics, and early cardiac effects. Mediolanum did not advance hexarelin to Phase III development. The compound entered the research chemical market, where it occupies a niche position relative to ipamorelin and GHRP-6 due to its desensitization profile.
Mechanism of Action
At GHS-R1a, hexarelin activates Gq/11 protein coupling, phospholipase C, IP3 production, and intracellular calcium release. The calcium signal drives GH exocytosis from pituitary somatotroph granules. Hexarelin’s higher affinity at GHS-R1a compared to GHRP-6—attributable to the D-2-MeTrp modification—produces larger GH responses per mole of compound. The same higher affinity drives more rapid receptor internalization and downregulation with repeated dosing, explaining the accelerated desensitization.
Hexarelin also produces hypothalamic effects through GHS-R1a receptors on somatostatin neurons, reducing somatostatin tone and amplifying the pituitary GH response. Cortisol and ACTH stimulation via GHS-R1a receptors in the adrenal and pituitary corticotroph populations is more pronounced with hexarelin than with other GHRPs—a consequence of its high GHS-R1a affinity engaging corticotroph GHS-R1a more fully.
Plain English
Hexarelin triggers GH release through the same calcium pathway as other GHRPs, but its stronger receptor grip also means it activates stress-hormone-producing cells more aggressively. More GH, but also more cortisol—and faster receptor burnout with repeated use.
The CD36 Receptor: Hexarelin’s Unique Cardioprotective Pathway
CD36 is a class B scavenger receptor expressed on the surface of cardiomyocytes, macrophages, platelets, and endothelial cells. It has multiple ligands and biological functions, including fatty acid uptake, oxidized LDL binding, and signaling roles in ischemic preconditioning. Hexarelin was identified as a CD36 ligand through experiments showing that its cardioprotective effects persisted in GH-deficient and GH receptor-knockout animals—ruling out any GH-mediated explanation and pointing to a direct receptor interaction in cardiac tissue.
The CD36-mediated cardioprotective mechanism involves activation of Src kinase and downstream anti-apoptotic signaling that reduces cardiomyocyte death during ischemia-reperfusion injury. In animal models, hexarelin administration before or after cardiac ischemia consistently reduces infarct size, preserves ejection fraction, and limits fibrotic remodeling. These are clinically meaningful endpoints if they translate to humans—which is the central unanswered question.
Plain English
In animal studies, hexarelin protects heart muscle during heart attacks by activating survival signals through a completely different receptor (CD36)—one that has nothing to do with growth hormone. Whether this works in humans is the big unanswered question.
Small human studies in patients with ischemic cardiomyopathy showed improvements in cardiac function parameters with hexarelin administration (Bisi et al. 1999). These are encouraging preliminary signals, not clinical evidence. No adequately powered RCT has evaluated hexarelin’s cardioprotective effects in humans against a control condition.
Why CD36 Matters
The CD36 mechanism means hexarelin has a potential clinical application—cardiac protection—that is entirely separate from its GH-axis effects and from its community use for body composition. If the animal cardioprotection data translates to humans, hexarelin becomes pharmacologically interesting in ways that no other compound in this cluster is. That translation is unproven. The mechanism is real and the animal data is consistent; the human evidence is preliminary.
Key Research Areas and Studies
GH stimulation in healthy adults and GH-deficient patients is well-documented. The Ghigo group in Turin produced extensive Phase I characterization of hexarelin’s GH response and desensitization kinetics. Cardiac research—primarily from Muccioli and colleagues—characterized the CD36 mechanism in animal models and small human studies. No Phase III data exists for any endpoint.
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Hexarelin is the most potent GH-releasing GHRP | Confirmed in comparative studies. Hexarelin produces larger GH AUC responses than GHRP-2 or GHRP-6 at equivalent doses in human and animal studies. This potency advantage comes with greater cortisol/ACTH stimulation and faster receptor desensitization. | Supported |
| Hexarelin has cardioprotective effects | CD36-mediated cardioprotective signaling is documented in animal models — reduced infarct size, improved cardiac function post-ischemia, anti-fibrotic effects. Human cardioprotection data is limited to small studies. The CD36 mechanism is real and distinct from GH-axis effects. | Preclinical / Limited Human Data |
| Hexarelin improves body composition | No controlled human body composition RCT. GH-mediated anabolic and lipolytic effects are class-level pharmacology. The rapid desensitization of hexarelin’s GH response limits sustained GH elevation versus other secretagogues. | Preclinical Only |
| Hexarelin is safe for long-term use | Rapid receptor desensitization with repeated dosing is documented — the GH response attenuates significantly within weeks of continuous use. This desensitization profile limits sustained utility and raises axis-recovery questions. No long-term human safety data. | Not Established |
| Hexarelin’s cardioprotective effects are independent of GH | Correct. CD36 binding and cardioprotective signaling occurs in GH-deficient animals and humans, confirming the mechanism is GH-axis independent. This is one of hexarelin’s scientifically distinctive features. | Supported |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
The Human Studies Landscape
Hexarelin has more published Phase I/II human data than GHRP-6 or GHRP-2 for its GH effects, and small human cardiac studies provide preliminary evidence for CD36-mediated benefits. What is missing is any Phase III trial for any endpoint. The desensitization problem—well-characterized in published human studies—limits the practical utility of hexarelin for sustained GH elevation protocols and has likely contributed to the absence of pharmaceutical development interest in long-term application.
The most scientifically significant gap is the human cardioprotection question. The animal data is compelling and mechanistically coherent. The human cardiac studies are small and uncontrolled. A well-designed Phase II cardioprotection trial would substantially clarify hexarelin’s clinical potential beyond GH axis pharmacology.
Safety, Risks, and Limitations
Cortisol and ACTH Stimulation
Hexarelin produces the most pronounced cortisol and ACTH stimulation of any GHRP—a documented finding from Phase I studies. This is a meaningful limitation for protocols targeting clean anabolic physiology, since elevated cortisol is catabolic. The effect is dose-dependent and acute; whether chronic hexarelin use produces meaningful HPA axis disruption is not established.
Receptor Desensitization
Hexarelin’s GH response attenuates faster than any other GHRP with repeated dosing. Published human studies document significant attenuation within weeks of continuous use. The mechanism is GHS-R1a internalization and downregulation driven by high-affinity sustained receptor activation. Recovery after cessation occurs but the time course is not precisely characterized. This limits hexarelin’s utility for protocols requiring maintained GH elevation over cycles of 8–12 weeks.
Plain English
Use hexarelin repeatedly and your pituitary stops responding as strongly—within weeks. The receptor essentially goes numb from overstimulation. This is why most protocols limit hexarelin to short cycles with long breaks.
Water Retention and GH Class Effects
Standard GH secretagogue class effects apply: water retention, potential insulin resistance with sustained GH elevation, and injection site reactions. These are attenuated by hexarelin’s rapid desensitization, which limits GH elevation duration.
WADA Prohibition
Hexarelin is prohibited under WADA S2: Peptide Hormones, Growth Factors, and Related Substances — both in-competition and out-of-competition. Athletes subject to anti-doping testing must treat this as a hard prohibition.
Legal and Regulatory Status
Hexarelin is FDA Category 3: not approved for any indication. It is classified as a research chemical. WADA prohibited under S2 both in- and out-of-competition.
Research Protocols and Laboratory Practices
Hexarelin is supplied as lyophilized powder, reconstituted with bacteriostatic water. Storage: 2–8°C (35–46°F) lyophilized; reconstituted solution refrigerated and used within 28 days. Standard subcutaneous injection technique. Rotate injection sites.
Reconstitution vs. Dosing Syringes
Use separate syringes for reconstitution and dosing. The 70-minute half-life means injection timing windows are more flexible than GHRP-6 but shorter than ipamorelin.
Dosing in Published Research
| Study / Source | Population | Dose | Route | Key Findings |
|---|---|---|---|---|
| Laron Z, et al. Clin Endocrinol 1995 | Healthy adults and GH-deficient patients | 1–2 µg/kg | IV bolus | Dose-dependent GH release; GH response greater than GHRP-6 at equivalent doses; cortisol and ACTH elevation confirmed |
| Muccioli G, et al. Endocrinology 2004 | Rat cardiac ischemia models | Various | IV/IP | CD36-mediated cardioprotection independent of GH; reduced infarct size; anti-apoptotic effects in cardiomyocytes |
| Bisi G, et al. J Clin Endocrinol Metab 1999 | Patients with ischemic cardiomyopathy (n=10) | 2 µg/kg IV | IV | Improved cardiac function parameters; increased ejection fraction trend; GH-independent mechanism consistent with CD36 pathway |
| Ghigo E, et al. J Clin Endocrinol Metab 1994 | Healthy adults | 0.1–2 µg/kg | IV | Desensitization documented — repeated dosing attenuated GH response; slower recovery vs. GHRP-6 |
Dosing in Independent Self-Experimentation Communities
| Protocol Parameter | Typical Community Range | Notes |
|---|---|---|
| Dose per injection | 100–200 µg | Lower than GHRP-2/GHRP-6 due to higher potency. Community avoids high doses because desensitization accelerates with increasing dose. |
| Frequency | 2× daily maximum; many use less frequently | Frequent dosing accelerates desensitization. Community often uses hexarelin on a less-frequent schedule than other GHRPs precisely to limit this. |
| Cycle approach | Short cycles (4–6 weeks) with extended breaks | Desensitization rationale — hexarelin’s GH response attenuates faster than ipamorelin or GHRP-6; breaks allow receptor recovery |
| Cardioprotective use | Sometimes used standalone at low dose for CD36 effects | Some community members use hexarelin specifically for its CD36 cardioprotective properties at doses below the full GH-stimulating range. This is mechanistically plausible but clinically unstudied in healthy adults. |
| Combination use | Less commonly combined with GHRH analogs than ipamorelin | The potency and desensitization profile makes hexarelin a less preferred combination partner than ipamorelin for GHRH + GHRP stacking. Some protocols use it short-term. |
Frequently Asked Questions
Why is hexarelin less popular than ipamorelin despite being more potent?
Potency is not always an advantage. Hexarelin’s higher GHS-R1a affinity drives faster receptor desensitization, greater cortisol/ACTH stimulation, and more rapid attenuation of the GH response with repeated use. Ipamorelin’s more moderate potency translates to a cleaner endocrine profile, slower desensitization, and a more sustained GH response across a typical 8–12 week protocol. For sustained-use community protocols, ipamorelin’s profile is more practical than hexarelin’s.
Can hexarelin protect the heart?
The animal evidence for CD36-mediated cardioprotection is consistent and mechanistically well-characterized. The human evidence is preliminary. It would be premature to recommend hexarelin for cardiac protection based on current data. The mechanism is real; the human translation is unproven.
Does hexarelin cause more cortisol than GHRP-2?
The comparative data is limited, but hexarelin generally produces the greatest cortisol and ACTH stimulation of any GHRP in published Phase I studies. GHRP-2 is also a significant cortisol stimulant. Both are more pronounced in this respect than ipamorelin.
Related Peptides: How Hexarelin Compares
| Compound | Receptor | Sequence/Type | MW | GH Potency | Appetite | Cortisol/ACTH | Half-life | FDA |
|---|---|---|---|---|---|---|---|---|
| GHRP-6 | GHS-R1a | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ | 873 Da | Moderate | Strong (hunger) | Moderate | ~15–20 min | Cat. 3 |
| GHRP-2 | GHS-R1a | His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ | 817 Da | Very strong | Moderate | Strong | ~30 min | Cat. 3 |
| Hexarelin | GHS-R1a + CD36 | His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ (hexapeptide) | 887 Da | Strongest GHRP | Moderate | Strongest GHRP | ~70 min | Cat. 3 |
| Ipamorelin | GHS-R1a | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | 712 Da | Moderate | Minimal | Minimal | ~2 hr | Cat. 3 |
| MK-677 | GHS-R1a | Non-peptide small molecule | 625 Da | Strong, sustained | Significant | Moderate | ~24 hr (oral) | Cat. 3 |
| Compound | Type | Receptor | GH Potency | Cortisol / ACTH | Appetite Effect | Half-Life | Route | FDA Status | WADA Status | Evidence Tier | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipamorelin | Synthetic pentapeptide GHS | GHS-R1a | Moderate | Minimal at research doses | Minimal | ~2 hr (subcutaneous) | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 2 — Clinical Trials (Phase I) | Most selective GHRP: GH release without cortisol, ACTH, or prolactin elevation at research doses |
| CJC-1295 (no DAC) | Synthetic GHRH analog (modified GRF 1-29) | GHRH-R | Moderate (amplifies when paired with GHS-R1a agonist) | None | None | ~30 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Short-acting GHRH analog; preserves pulsatile GH physiology. Pharmacologically paired with ipamorelin via complementary receptor pathway |
| CJC-1295 (with DAC) | Synthetic GHRH analog with Drug Affinity Complex | GHRH-R | Strong (sustained) | None | None | ~6–8 days | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 2 — Clinical Trials (Phase I/II) | DAC extends half-life to ~1 week; produces sustained (non-pulsatile) GH elevation. NOT interchangeable with no-DAC version |
| Sermorelin | Synthetic GHRH analog (GRF 1-29) | GHRH-R | Moderate | None | None | ~10–20 min | Subcutaneous injection | Previously FDA-approved (Geref); discontinued commercially | Prohibited — S2 | Tier 1 — Approved (historically) | Only GH secretagogue with prior FDA approval history. Very short half-life limits practical utility |
| MK-677 (Ibutamoren) | Non-peptide GHS (spiroindoline) | GHS-R1a | Strong (sustained over 24 hr) | Transient mild elevation | Significant (hunger, weight gain) | ~4–6 hr (oral bioavailability) | Oral | Category 3 — not FDA-approved | Prohibited — S2 | Tier 2 — Clinical Trials (Phase II) | Only orally bioavailable GHS-R1a agonist. Most extensive human clinical dataset in the class. Appetite and insulin resistance are dose-limiting |
| GHRP-2 | Synthetic hexapeptide GHS | GHS-R1a | Strong (most potent classic GHRP) | Significant — cortisol and ACTH stimulation | Moderate | ~25–30 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Most potent GH release of classic GHRPs, but cortisol/ACTH co-stimulation works against anabolic intent |
| GHRP-6 | Synthetic hexapeptide GHS | GHS-R1a | Strong | Significant — cortisol and ACTH stimulation | Strong (intense hunger) | ~15–20 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | First widely used GHRP. Intense appetite stimulation mirrors ghrelin signaling. Least selective of the class |
| Hexarelin | Synthetic hexapeptide GHS | GHS-R1a | Strong | Significant — cortisol and ACTH stimulation | Moderate | ~70 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Rapid receptor desensitization limits sustained use. GH response attenuates more steeply over repeated dosing than other GHRPs |
Summary and Key Takeaways
- Hexarelin is the most potent GHS-R1a agonist GHRP, producing the largest GH responses but also the most cortisol/ACTH stimulation and the fastest receptor desensitization.
- A second mechanism—CD36 receptor binding—mediates cardioprotective effects independent of the GH axis. This is pharmacologically distinctive and scientifically significant.
- The desensitization profile limits hexarelin’s utility for sustained community protocols. Short cycles with extended breaks are the standard approach when it is used.
- Human cardiac data is preliminary. The CD36 cardioprotection mechanism is real; human clinical validation is absent.
- FDA Category 3. WADA prohibited under S2 both in- and out-of-competition.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References
- Ghigo E, et al. Hexarelin, a new synthetic GH-releasing peptide, is a potent stimulator of GH secretion in humans. J Clin Endocrinol Metab. 1994;79(4):943–8.
- Laron Z, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(6):631–5.
- Bisi G, et al. Cardiovascular effects of hexarelin in GH-deficient patients. J Clin Endocrinol Metab. 1999;84(9):3100–3.
- Muccioli G, et al. Hexarelin: a synthetic peptide that reverses cardiac dysfunction. Endocrinology. 2004;145(10):4823–33.
- Rossoni G, et al. Hexarelin protects against cardiac ischemic injury. Br J Pharmacol. 2000;131(1):1–8.
Further Reading
- Ipamorelin article — peptidings.com/peptides/ipamorelin/
- GHRP-2 article — peptidings.com/peptides/ghrp-2/
- GHRP-6 article — peptidings.com/peptides/ghrp-6/
- Growth Hormone Secretagogues Cluster Hub — peptidings.com/peptides/growth-hormone-secretagogues/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
Hexarelin information is provided for research and educational purposes only. Readers are responsible for understanding and complying with all applicable laws in their jurisdiction.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.
← Previous
Next →